June, 2023
RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
View News May, 2023
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News May, 2023
RayzeBio to Present at Upcoming Medical Conferences
View News March, 2023
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
View News March, 2023
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News January, 2023
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
View News January, 2023
RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
View News December, 2022
RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors
View News November, 2022
RayzeBio to Present at Upcoming Investor Conferences in November 2022
View News September, 2022
RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications
View News September, 2022
RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer
View News August, 2022
PeptiDream and RayzeBio Announce Expansion of Strategic Partnership for the Discovery of Novel Peptide Radiopharmaceutical Therapeutics
View News April, 2022
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors
View News January, 2022
RayzeBio Expands Leadership Team with Arvind Kush, as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel
View News January, 2022
RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022
View News October, 2021
RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality
View News August, 2021
RayzeBio Expands Leadership Team with Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation
View News July, 2021
48Hour Discovery and RayzeBio Announce strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
View News June, 2021
Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
View News June, 2021
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
View News April, 2021
RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires
View News December, 2020
RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer
View News October, 2020
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
View News August, 2020
PeptiDream Announces Strategic Partnership with RayzeBio for the Discovery and Development of Peptide-Radiotherapeutics
View News June, 2023
RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
View News May, 2023
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News May, 2023
RayzeBio to Present at Upcoming Medical Conferences
View News March, 2023
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
View News March, 2023
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News January, 2023
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
View News January, 2023
RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
View News December, 2022
RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors
View News November, 2022
RayzeBio to Present at Upcoming Investor Conferences in November 2022
View News September, 2022
RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications
View News September, 2022
RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer
View News August, 2022
PeptiDream and RayzeBio Announce Expansion of Strategic Partnership for the Discovery of Novel Peptide Radiopharmaceutical Therapeutics
View News April, 2022
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors
View News January, 2022
RayzeBio Expands Leadership Team with Arvind Kush, as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel
View News January, 2022
RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022
View News October, 2021
RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality
View News August, 2021
RayzeBio Expands Leadership Team with Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation
View News July, 2021
48Hour Discovery and RayzeBio Announce strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
View News June, 2021
Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
View News June, 2021
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
View News April, 2021
RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires
View News December, 2020
RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer
View News October, 2020
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
View News August, 2020
PeptiDream Announces Strategic Partnership with RayzeBio for the Discovery and Development of Peptide-Radiotherapeutics
View News
